(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual revenue growth rate of 8.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Vertex Pharmaceuticals's revenue in 2025 is $11,099,700,000.On average, 11 Wall Street analysts forecast VRTX's revenue for 2025 to be $3,057,553,139,044, with the lowest VRTX revenue forecast at $3,043,560,260,324, and the highest VRTX revenue forecast at $3,070,780,762,146. On average, 11 Wall Street analysts forecast VRTX's revenue for 2026 to be $3,357,566,724,644, with the lowest VRTX revenue forecast at $3,184,285,118,800, and the highest VRTX revenue forecast at $3,840,016,735,805.
In 2027, VRTX is forecast to generate $3,630,280,201,294 in revenue, with the lowest revenue forecast at $3,372,440,417,715 and the highest revenue forecast at $4,330,884,558,755.